$100M to $250M is "sweet spot" for pharma venture funds

06/20/2013 | Genetic Engineering & Biotechnology News

Half of the 20 drugmaker venture capital funds on this list report total resources of between $100 million and $250 million. GlaxoSmithKline, Pfizer, Novartis, Sanofi, Merck and Boehringer Ingleheim are among the drugmakers starting or investing in venture capital funds for new drug discovery.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ